Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted pipeline therapeutics. 

The report provides comprehensive information on the Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)
- The report reviews Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Overview 6
Therapeutics Development 7
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Stage of Development 7
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Therapy Area 8
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Indication 9
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Companies 12
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Companies Involved in Therapeutics Development 20
Crescendo Biologics Limited 20
Exicure, Inc. 21
Novartis AG 22
Teva Pharmaceutical Industries Ltd. 23
UCB S.A. 24
Vipergen ApS 25
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Drug Profiles 26
Antisense Oligonucleotide to Antagonize IL-17RA for Inflammatory Disorders - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
bimekizumab - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CB-001 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
E-34935 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
E-35018 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
E-35762 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
E-36041 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Recombinant Protein to Inhibit IL-17A for Psoriasis - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Antagonize IL-17A for Inflammatory and Autoimmune Diseases - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Dormant Projects 36
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Featured News & Press Releases 37
Jun 10, 2016: UCB's bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis 37
Jun 08, 2016: UCB presents Phase 1b data on Bimekizumab at the Annual European Congress of Rheumatology (EULAR 2016) 38
Sep 01, 2013: Vipergen presents first discovery of small molecule IL-17A antagonists 38
Apr 01, 2013: Ensemble Therapeutics To Present Preclinical Data On IL-17A Inhibitors At 245th ACS National Meeting 39
Nov 12, 2012: Ensemble Therapeutics Presents Oral Efficacy Of Small Molecule Targeting IL-17 For Inflammation In Preclinical Studies 39
Oct 29, 2012: Ensemble Therapeutics To Present Poster On Interleukin-17 At 2012 ACR Annual Meeting 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 19
Pipeline by Crescendo Biologics Limited, H2 2016 20
Pipeline by Exicure, Inc., H2 2016 21
Pipeline by Novartis AG, H2 2016 22
Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 23
Pipeline by UCB S.A., H2 2016 24
Pipeline by Vipergen ApS, H2 2016 25
Dormant Projects, H2 2016 36